Characteristics of subjects (n = 21), CBF measurements in mL/100 mL/min, and WMH score
| Subjects | Sex | Age | Diagnosis | Medication and Drugs | Cortical CBF | Subcortical CBF | Global CBF | WMH† |
|---|---|---|---|---|---|---|---|---|
| 1 | F | 73 | – | Diuretic | 64.1 | 37.1 | 50.5 | 1 |
| 2 | M | 70 | – | Diuretic | 65.7 | 38.4 | 52.1 | 1 |
| 3 | F | 78 | – | – | 69.6 | 40.4 | 54.8 | 1 |
| 4 | F | 79 | – | Diuretic | 68.5 | 48.6 | 58.0 | 1 |
| 5 | F | 76 | AD | AA, nicotine | 57.6 | 34.2 | 44.4 | 2 |
| 6 | F | 82 | AD | β-Bl | 61.6 | 34.4 | 46.2 | 2 |
| 7 | F | 80 | – | – | 62.1 | 37.1 | 47.9 | 2 |
| 8 | F | 78 | – | – | 55.5 | 41.4 | 47.9 | 2 |
| 9 | M | 75 | – | Diuretic, CA | 66.8 | 39.4 | 51.4 | 2 |
| 10 | F | 66 | – | AA | 70.7 | 51.5 | 60.0 | 2 |
| 11 | M | 73 | – | – | 72.5 | 47.8 | 60.4 | 2 |
| 12 | F | 70 | – | α2-agonist | 81.2 | 48.1 | 62.9 | 2 |
| 13 | F | 70 | – | β-Bl, nitrate | 77.1 | 53.3 | 64.4 | 2 |
| 14 | F | 72 | – | CA*, nitrate | 106.1 | 60.2 | 78.9 | 2 |
| 15 | M | 80 | – | β-Bl, CA | 51.3 | 26.7 | 36.2 | 3 |
| 16 | M | 70 | – | β-Bl, CA | 48.7 | 26.9 | 37.8 | 3 |
| 17 | F | 84 | – | Diuretic, β-Bl, AA, nitrate | 47.6 | 35.0 | 40.6 | 3 |
| 18 | M | 76 | VaD | Diuretic, ACE inhibitor | 62.3 | 31.7 | 40.9 | 3 |
| 19 | M | 84 | – | ACE inhibitor | 60.6 | 35.2 | 46.3 | 3 |
| 20 | M | 71 | – | Diuretic, β-Bl | 65.3 | 37.0 | 49.4 | 3 |
| 21 | F | 79 | – | – | 69.1 | 42.9 | 53.1 | 3 |
| Mean (SD) | – | 75.5 (5.1) | – | – | 65.9 (12.6) | 40.3 (8.6) | 51.6 (10.1) | 2.1 (0.7) |
Note:—AD indicates Alzheimer disease; VaD, vascular dementia; AA, angiotensin antagonist; β-Bl, β-blocker; CA*, calcium antagonist (*diltiazem); ACE inhibitor, angiotensin-converting enzyme inhibitor; WMH, white matter hyperintensities; CBF, cerebral blood flow.
† Higher values indicate greater severity.